

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtt. No.  
60772-PCT-USSerial No.  
09/768,872O I P  
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

JUL 05 2002

Applicants

Rina Aharoni et al.

Filing Date

January 23, 2001

Group Art Unit  
1644

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
AD	US 3 8 4 9 5 5 0	11/19/74	Teitelbaum et al.	—	—	—
	US 4 3 3 9 4 3 1	7/13/82	Gaffar	—	—	—
	US 5 2 0 4 0 9 9	4/20/93	Barbier et al.	—	—	—
	US 5 5 9 1 6 2 9	1/7/97	Rodriguez et al.	—	—	—
	US 5 6 2 7 2 0 6	5/6/97	Hupe et al.	—	—	—
↓	US 5 6 6 8 1 1 7	9/16/97	Shapiro et al.	—	—	—

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
AD	WO 8 8 1 0 1 2 0	12/29/88	US		—	—		
	WO 9 5 3 1 9 9 0	11/30/95	US		—	—		
	WO 9 5 3 3 4 7 5	12/14/95	Europe		—	—		
	WO 9 8 3 0 2 2 7	7/16/98	US		—	—		
	WO 0 0 0 5 2 4 9	2/3/00	US		—	—		
↓	WO 0 0 0 5 2 5 0	2/3/00	US		—	—		

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AD	Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Polypeptide", <u>Eur. J. Immunol.</u> , 1971, 1, 242-248
	Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Polypeptide", <u>Israel J. Med. Sci.</u> , 1971, 7, 630-631 (Abstract)
	Arnon, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Copolymer Immunological Cross Reactive with Basic Encephalitogen", <u>Israel J. Med. Sci.</u> , 1972, 8, 1759-1760
	Teitelbaum, et al., "Protection Against Experimental Allergic Encephalomyelitis", <u>Nature</u> , 1972, 240, 564-566
↓	Webb, et al., "Further Studies on the Suppression of Experimental Allergic Encephalomyelitis by Synthetic Copolymer", <u>Israel J. Med. Sci.</u> , 1972, 8, 656-657

EXAMINER

*John D. Cleary*

DATE CONSIDERED

6-22-02

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED  
JUL 09 2002  
TECH CENTER 1644

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office								Atty. Docket No. 60772-PCT-US	Serial No. 09/768,872
		INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)								Applicants Rina Aharoni et al.	
										Filing Date January 23, 2001	Group Art Unit 1644



U.S. PATENT DOCUMENTS												
Examiner's Initial		Document Number						Date	Name	Class	Subclass	Filing Date if Appropriate
AB	US	5	7	1	9	2	9	6	2/17/98	Acton III, et al.	—	—
	US	5	8	0	0	8	0	8	9/1/98	Konfino et al.	—	—
	US	5	8	5	8	9	6	4	1/12/99	Aharoni et al.	—	—
	US	5	9	8	1	5	8	9	11/9/99	Konfino et al.	—	—
	US	5	9	5	8	9	7	2	9/28/99	Hupe et al.	—	—
	US	6	0	4	8	8	9	8	4/11/00	Konfino et al.	—	—
	US	6	0	5	4	4	3	0	4/25/00	Konfino et al.	—	—
	US	6	2	1	4	7	9	1	4/10/01	Arnon et al.	—	—
	US	6	3	4	2	4	7	6	1/29/02	Konfino et al.	—	—
✓	US	20	01	00	55	56	8	A1	12/27/01	Gilbert et al.	—	—

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation					
							Yes	No				
AB	WO	0	0	1	8	7	9	4	4/6/00	US	—	—
	WO	0	0	2	0	0	1	0	4/13/00	US	—	—
	WO	0	0	2	7	4	1	7	5/18/00	US	—	—
	WO	0	1	6	0	3	9	2	8/23/01	US	—	—
	WO	0	1	9	3	8	2	8	12/13/01	US	—	—
	WO	0	1	9	7	8	4	6	12/27/01	US	—	—

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AB	Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis with Basic Polymers", <u>Eur. J. Immunol.</u> , 1973, 3, 273-279
	Webb, et al., "In Vivo and in Vitro Immunological Cross-reactions between Basic Encephalitogen and Synthetic Basic Polypeptides Capable of Suppressing Experimental Allergic Encephalomyelitis", <u>Eur. J. Immunol.</u> , 1973, 3, 279-286
	Teitelbaum, et al., "Dose-response Studies on Experimental Allergic Encephalomyelitis Suppression by COP-1", <u>Israel J. Med. Sci.</u> , 1974, 10(9), 1172-1173

EXAMINER	DATE CONSIDERED
<i>Ami Dahan</i>	4-27-02

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtt. No.  
60772-PCT-USSerial No.  
09/768,872INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

JUL 05 2002

## Applicants

Rina Aharoni et al.

Filing Date  
January 23, 2001Group Art Unit  
1644

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
AD	US 09 3 5 9 0 9 9	7/22/99	Strominger et al.	—	—	—
↓	US 09 4 0 5 7 4 3	9/24/99	Gad et al.	—	—	—
↓	US 09 8 1 6 9 8 9	3/23/01	Gad et al.	—	—	—
↓	US 09 8 7 5 4 2 9	6/5/01	Yong and Chabot.	—	—	—
↓	US 09 8 8 5 2 2 7	6/20/01	Rodriguez and Ure.	—	—	—

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
AN	EP 0 3 8 3 6 2 0	8/22/90	Europe				
↓	EP 0 3 5 9 7 8 3	11/29/95	Europe				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AD	Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis in Rhesus Monkeys by a Synthetic Basic Copolymer", <u>Clin. Immunol. Immunopath.</u> , 1974, <u>3</u> , 256-262
↓	Webb, et al., "Suppression of Experimental Allergic Encephalomyelitis in Rhesus Monkeys by a Synthetic Basic Copolymer", <u>Isr. J. Med. Sci.</u> , 1975, <u>11</u> , 1388 (Abstract)
	Webb, et al., "Molecular Requirements Involved in Suppression of EAE by Synthetic Basic Copolymers of Amino Acids", <u>Immunochem.</u> , 1976, <u>13</u> , 333-337
	Abramsky, et al., "Effect of a Synthetic Polypeptide (COP-1) on Patients with Multiple Sclerosis and with Acute Disseminated Encephalomyelitis", <u>J. Neurol. Sci.</u> , 1977, <u>31</u> , 433-438
	Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis in Baboons by Cop 1", <u>Israel J. Med. Sci.</u> , 1977, <u>13</u> , 1038 (Abstract)
	Arnon, et al., "Suppression of EAE in Baboons by a Synthetic Polymer of Amino Acids", <u>Neurol.</u> , 1978, <u>28</u> , 336 (Abstract)
	Sela, et al., "Experimental Allergic Encephalomyelitis" in <u>Menarini Series on Immunopathology</u> , vol. 1, First Symposium of <u>Organ Specific Autoimmunity</u> , Cremona, Italy, June, 1977, (Miescher P.A. ed., Schwabe Co., Basel, 1978), 9-21
↓	Alvord, et al., "Myelin Basic Protein Treatment of Experimental Allergic Encephalomyelitis in Monkeys", <u>Ann. Neurol.</u> , 1979, <u>6</u> , 469-473

EXAMINER

DATE CONSIDERED

Amy DePew 5/22/02

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED  
JUL 09 2002  
TECH CENTER

Form PTO-1449


U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.  
60772-PCT-US

Serial No.  
09/768,872

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)



Applicants  
**Rina Aharoni et al.**

Filing date  
**January 23, 2001**

Group Art Unit  
**1644**

**OTHER DOCUMENTS (Including Author, Date, Pertinent Pages, Etc.)**

A7)	Keith, et al., "The Effect of COP 1, a Synthetic Polypeptide, on Chronic Relapsing Experimental Allergic Encephalomyelitis in Guinea Pigs" <u>J. Neurol. Sci.</u> , 1979, <u>42</u> , 267-274
	Lando, et al., "Effect of Cyclophosphamide on Suppressor Cell Activity in Mice Unresponsive to EAE", <u>J. Immunol.</u> , 1979, <u>123</u> , 2156-2160. (Abstract)
	Lando et al., "Experimental Allergic Encephalomyelitis in Mice - Suppression and Prevention with COP-1", <u>Israel J. Med. Sci.</u> , 1979, <u>15</u> , 868-896 (Abstract)
	Teitelbaum, et al., "Blocking of Sensitization to Encephalitogenic Basic Protein in Vitro by Synthetic Basic Copolymer (COP 1)" in <u>Cell Biology and Immunology of Leukocyte Function</u> (Academic Press, New York, 1979) 681-685
	Teitelbaum, "Suppression of Experimental Allergic Encephalomyelitis with a Synthetic Copolymer - Relevance to Multiple Sclerosis", in <u>Humoral Immunity in Neurological Diseases</u> (Karcher D., Lowenthal A. & Strosberg A.D., eds., Plenum Publishing Corp., 1979) 609-613
	Arnon, et al., "Desensitization of Experimental Allergic Encephalomyelitis with Synthetic Peptide Analogs" in <u>The Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis</u> (Academic Press, New York, 1980) 105-107
	Arnon, "A Synthetic Copolymer of Amino Acids in a Clinical Trial for MS Therapy" in <u>Progress in Multiple Sclerosis Research</u> (Bauer, Ritter, eds., Springer Verlag New York, 1980) 416-418
	Bornstein, et al., "Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminary Results", <u>Ann. Neurol.</u> , 1980, <u>8</u> , 117 (Abstract)
	Bornstein, et al., "Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminary Results", <u>Trans. Am. Neurol. Assoc.</u> , 1980, <u>105</u> , 348-350
	McDermott, et al., "Antigen-induced Suppression of Experimental Allergic Neuritis in the Guinea Pig", <u>J. Neurol. Sci.</u> , 1980, <u>46</u> , 137-143
	Arnon, "Experimental Allergic Encephalomyelitis - Susceptibility and Suppression", <u>Immunological Rev.</u> , 1981, <u>55</u> , 5-30
	Bornstein et al., "Multiple Sclerosis: Trial of a Synthetic Polypeptide", <u>Ann. Neurol.</u> , 1982, <u>11</u> , 317-319

EXAMINER

DATE CONSIDERED

8-77-02

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED  
JUL 09 2002  
TECH CENTER 1600/ma.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. <b>60772-PCT-US</b>	Serial No. <b>09/768,872</b>
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)		O I P E JUL 05 2002 TRADEMAKES		Applicants <b>Rina Aharoni et al.</b>	
				Filing date <b>January 23, 2001</b>	Group Art Unit <b>1644</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>					
<p>Brosnan, et al., "The Response of Normal Human Lymphocytes to Copolymer 1", <u>J. Neuropath. Exp. Neurol.</u>, 1983, <u>42</u>, 356 (Abstract)</p> <p>Lisak, et al., "Effect of Treatment with Copolymer 1 (Cop-1) on the in Vivo and in Vitro Manifestations of Experimental Allergic Encephalomyelitis (EAE)", <u>J. Neurol. Sci.</u>, 1983, <u>62</u>, 281-293</p> <p>Bornstein, et al., "Clinical Trials of Copolymer 1 in Multiple Sclerosis", <u>Ann. N.Y. Acad. Sci. (USA)</u>, 1984, 366-372</p> <p>Bornstein, et al., "Clinical Trials of a Synthetic Polypeptide (Copolymer 1) for the Treatment of Multiple Sclerosis" in Gonsett et al., <u>Immunological and Clinical Aspects of Multiple Sclerosis</u> (MTP Press, The Hague, 1984) 144-150</p> <p>Brosnan, et al., "Copolymer 1: Effect on Normal Human Lymphocytes", <u>Ann. N.Y. Acad. Sci. (USA)</u>, 1984, <u>436</u>, 498-499</p> <p>Bornstein, et al., "Multiple Sclerosis: Clinical Trials of a Synthetic Polypeptide, Copolymer 1", <u>Neurol.</u>, 1985, <u>35</u> (Suppl. 1), 103 (Abstract)</p> <p>Brosnan, et al., "Immunogenic Potentials of Copolymer 1 in Normal Human Lymphocytes", <u>Neurol.</u>, 1985, <u>35</u>, 1754-1759</p> <p>Burns, et al., "Human Cellular Immune Response in Vitro to Copolymer 1 and Myelin Basic Protein (MBP)", <u>Neurol.</u>, 1985, <u>35</u> (Suppl. 1), 170 (Abstract)</p> <p>Teitelbaum, et al., "Monoclonal Antibodies to Myelin Basic Protein Cross React with Synthetic EAE-suppressive Copolymer, COP 1" in <u>Proc. 7<sup>th</sup> Eur. Immunol. Mtg.</u>, Jerusalem, September 8-13, 1985 (Abstract)</p> <p>Thompson, "MCQ Tutor: Medical Immunology Multiple Choice Questions", <u>Immunol. Today</u>, 1985, <u>6</u>(4), 141</p> <p>Burns, et al., "Human Cellular Immune Response to Copolymer 1 and Myelin Basic Protein", <u>Neurol.</u>, 1986, <u>36</u>, 92-94</p> <p>Bornstein, "Cop 1 May be Beneficial for Patients with Exacerbating-remitting Form of Multiple Sclerosis", <u>Adv. Ther. (USA)</u>, 1987, <u>4</u>, 206 (Abstract)</p> <p>Bornstein, et al., "A Pilot Trial of Cop 1 in Exacerbating-remitting Multiple Sclerosis", <u>New Eng. J. Med.</u>, 1987, <u>317</u>(7), 408-414</p> <p>Rolak, "Copolymer-I Therapy for Multiple Sclerosis", <u>Clin. Neuropharmacology</u>, 1987, <u>10</u>(5), 389-396</p> <p>Winer, "COP 1 Therapy for Multiple Sclerosis", <u>New Eng. J. Med.</u>, 1987, <u>317</u>(7), 442-444</p>					
EXAMINER <i>Anna Delaney</i>	DATE CONSIDERED <i>8-7-02</i>				
<p><b>*EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>					

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
60772-PCT-USSerial No.  
09/768,872

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

JUL 05 2002

Applicants

Rina Aharoni et al.

Filing date

January 23, 2001

Group Art Unit

1644

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Arnon, et al., "Suppression of Demyelinating Diseases by Synthetic Copolymers", in <u>A Multidisciplinary Approach to Myelin Disease</u> (G. Serlupi Crescenzi, ed., Plenum Publishing Corp., 1988) 243-250
Baumhefner, et al., "Copolymer 1 as Therapy for Multiple Sclerosis: The Cons", <u>Neurol.</u> , 1988, <u>38</u> (Suppl. 2), 69-71
Bornstein, et al., "Clinical Experience with COP-1 in Multiple Sclerosis", <u>Neurol.</u> , 1988, <u>38</u> (Suppl. 2), 66-69
Teitelbaum, et al., "Specific Inhibition of the T-cell Response to Myelin Basic Protein by the Synthetic Copolymer Cop 1", <u>Proc. Natl. Acad. Sci. USA</u> , 1988, <u>85</u> , 9724-9728
Arnon, et al., "Suppression of Experimental Allergic Encephalomyelitis by Cop-1 - Relevance to Multiple Sclerosis", <u>Israel J. Med. Sci.</u> , 1989, <u>25</u> , 686-689
Bornstein, et al., "Pilot Trial of COP-1 in Chronic Progressive Multiple Sclerosis: Preliminary Report", from <u>The International Multiple Sclerosis Conference: An Update on Multiple Sclerosis</u> , Roma (Italy), September 15-17, 1988, in <u>Elsevier Science Publisher</u> , 1989, 225-232
Teitelbaum, et al., "Clinical Trial of Copolymer 1 in Multiple Sclerosis" <u>J. Israel Med. Assoc.</u> , 1989, <u>CXVI</u> (9), 453-456
Bornstein, et al., "Clinical Trials of Cop 1 in Multiple Sclerosis" in <u>Handbook of Multiple Sclerosis</u> (S.D. Cook Marcel Rekker, ed., 1990) 469-480
Carter, et al., "Newer Drug Therapies for Multiple Sclerosis", <u>Drug Therapy</u> , 1990, 31-32, 37-39, 42-43
Grgacic, et al., "Cell-mediated Immune Response to Copolymer 1 in Multiple Sclerosis Measured by the Macrophage Procoagulant Activity Assay", <u>Int. Immunol.</u> , 1990, <u>2</u> (8), 713-718
Kay, et al., "The Mechanism of Action of FK 506", <u>Transplantation Proceedings</u> , 1990, <u>22</u> (1, Suppl. 1), 96-99
Lee, et al., "Peptide and Protein Drug Delivery" in <u>Advances in Parenteral Sciences</u> (Vincent H.L. Lee, ed., Marcel Dekker, Inc., 1990) 691-695
Myers, et al., "The Peculiar Difficulties of Therapeutic Trials for Multiple Sclerosis", <u>Neurologic Clinics</u> , 1990, <u>8</u> (1), 119-141
Sela, et al., "Suppressive Activity of COP-1 in EAE and its Relevance to Multiple Sclerosis", <u>Bull. Inst. Pasteur</u> , 1990, <u>88</u> , 303-314

EXAMINER

DATE CONSIDERED

8-27-02

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeDocket No.  
60772-PCT-USSerial No.  
09/768,872INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicants  
Rina Aharoni et al.Filing date  
January 23, 2001Group Art Unit  
1644

## OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Pages, Etc.)

<i>A</i>	Starzl, <u>Transplantation Proceedings</u> , 1990, <u>22</u> (1, Suppl. 1), 5
	Wender, "Copolymer 1 (COP-1) in the Treatment of Multiple Sclerosis (letter)" <u>Neur. Neurochir. Pol.</u> , 1990, <u>24</u> , 113
	Bornstein, et al., "A Placebo-controlled, Double-blind, Randomized Two-center, Pilot Trial of Cop 1 in Chronic Progressive Multiple Sclerosis", <u>Neurol.</u> , 1991, <u>41</u> , 533-539
	Burns, et al., "Failure of Copolymer 1 to Inhibit the Human T-cell Response to Myelin Basic Protein", <u>Neurol.</u> , 1991, <u>41</u> , 1317-1319
	Clinical Trial Protocol No. 9001, Teva Pharmaceutical Industries, Ltd., first patient enrolled October 23, 1991
	Ferrara, et al., "Graft-Versus-Host Disease", <u>New Eng. J. Med.</u> , 1991, <u>324</u> , 667-674
	Meiner, "COP-1 Multicenter Clinical Trial in Exacerbating-remitting Multiple-Sclerosis: One Year Follow-up", <u>J. Neurol.</u> , 1991(Suppl. 1) (Abstract)
	Rothbard, et al., "Interactions Between Immunogenic Peptides and MHC Proteins", <u>Ann. Rev. Immunol.</u> , 1991, <u>9</u> , 527-565
	Salvetti, et al., "Myelin Basic Protein T Cell Epitopes in Patients with Multiple Sclerosis", <u>Department of Neurological Sciences, University of Rome, La Sapienza</u> 1991, <u>72</u> (Abstract)
	Teitelbaum, et al., "Cross-reactions and Specificities of Monoclonal Antibodies Against Myelin Basic Protein and Against the Synthetic Copolymer 1", <u>Proc. Natl. Acad. Sci. (USA)</u> , 1991, <u>88</u> , 9528-9532
	Van den Bogaerde, et al., "Induction of Long-Term Survival of Hamster Heart Xenografts in Rats", <u>Transplantation</u> , 1991, <u>52</u> , 15-20
	Bornstein et al., "Treatment of Multiple Sclerosis with Copolymer 1" in <u>Treatment of Multiple Sclerosis: Trial Design, Results and Future Perspectives</u> (Rudick R.A. & Goodkin D.E., eds., Springer Verlag, London, 1992, 173-198
	Johnson, "Clinical Studies in Copolymer 1 Therapy for Exacerbating-remitting Multiple Sclerosis", in <u>Congress for Advances in the Understanding and Treatment of Multiple Sclerosis</u> , Boston (USA), Oct. 28-29, 1992
	Milo, et al., "Inhibition of Myelin Basic Protein-specific Human T-cell Lines by COP-1", <u>Israel J. Med. Sci.</u> , 1992, <u>28</u> , 486 (Abstract)

EXAMINER

DATE CONSIDERED

*5-27-01*

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*RECEIVED*  
JUL 09 2002  
TECH CENTER 1600/2900

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeDocket No.  
60772-PCT-USSerial No.  
09/768,872INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

JUL 05 2002

Applicants  
Rina Aharoni et al.Filing date  
January 23, 2001Group Art Unit  
1644

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

A9	Racke, et al., "Copolymer-1-induced Inhibition of Antigen-specific T Cell Activation: Interference with Antigen Presentation", <u>J. Neuroimmunol.</u> , 1992, <u>37</u> , 75-84
	Teitelbaum, et al., "Synthetic Copolymer 1 Inhibits Human T-cell Lines Specific for Myelin Basic Protein", <u>Proc. Natl. Acad. Sci. (USA)</u> , 1992, <u>89</u> , 137-141
	Weinshenker, et al., "Natural History and Treatment of Multiple Sclerosis", <u>Current Opinion in Neurol. and Neurosurgery</u> , 1992, <u>5</u> , 203-211
	Aharoni, et al., "T Suppressor Hybridomas and Interleukin-2-Dependent Lines Induced by Copolymer 1 or by Spinal Cord Homogenate Down-Regulate Experimental Allergic Encephalomyelitis", <u>Eur. J. Immunol.</u> , 1993, <u>23</u> , 17-25
	Arnon, et al., "Immunomodulation of Experimental Allergic Encephalomyelitis", <u>Israel J. Med. Sci.</u> , 1993, <u>29</u> , 175-181
	Arnon, et al., "On the Existence of Suppressor Cells", <u>Int. Arch. Allergy Immunol.</u> , 1993, <u>100</u> , 2-7
	Clinical Trial Protocol No. 9002, Lemmon Co. and Teva Pharmaceutical Industries, Ltd., first patient enrolled June 17, 1993
	Francis, "The Current Therapy of Multiple Sclerosis", <u>J. Clin. Pharmacy and Therapeutics</u> , 1993, <u>18</u> , 77-84
	Keleman, et al., "Graft-versus-Host Disease in Bone Marrow Transplantation: Experimental, Laboratory, and Clinical Contributions of the Last Few Years", <u>Int. Arch. Allergy Immunol.</u> , 1993, <u>102</u> , 309-320
	Gurevich, "Study of the MHC-competition Between BP and Cop 1 Using Human Cytotoxic T-cell Clones", <u>Israel J. Med. Sci.</u> , 1993 (Abstract)
	Meiner et al., "The Israeli COP-1 Multicenter Clinical Trial in Exacerbating-remitting Multiple Sclerosis - Two year Follow-up", in <u>9th Congress of the European Committee for Treatment and Research in Multiple Sclerosis</u> , Florence (Italy), October-November, 1993, 48 (Abstract)
✓	Milo, et al., "Copolymer-1 (COP-1) Regulates Class II MHC Expression and Cytokine Synthesis in the THP-1 Monocyte-Macrophage Cell Line" in <u>The IBC Conference on Multiple Sclerosis</u> , San Diego (USA), December 10, 1993 (Abstract)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeDocket No.  
60772-PCT-USSerial No.  
09/768,872

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

JUL 05 2002

Applicants

Rina Aharoni et al.

Filing date

January 23, 2001

Group Art Unit

1644

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Sela, "Polymeric Drugs as Immunomodulatory Vaccines Against Multiple Sclerosis", <u>Makromol. Chem. Macromol. Symp.</u> , 1993, <u>70/71</u> , 147-155
	Arnon, et al., "Immunospecific Drug Design - Prospects for Treatment of Autoimmune Disease", <u>Therapeutic Immunol.</u> , 1994, <u>1</u> , 65-70
	Bansil, et al., "Multiple Sclerosis: Pathogenesis and Treatment", <u>Seminars in Neurol.</u> , June 1994, <u>14</u> (2), 146-153
	The COP-1 Multicenter Clinical and Research Group Study, "COP-1 Multicenter Trial in Relapsing Remitting Multiple Sclerosis: 3 Year Follow Up", <u>Abstracts of Symposia and Free Communication</u> , Barcelona (Spain), June 25-29, 1994, <u>241</u> (Suppl. 1), 6
	Cotton, "Options for Multiple Sclerosis Therapy", <u>J.A.M.A. Medical News &amp; Perspectives</u> , 1994, <u>272</u> (18), 1393
	Dorling, et al., "Prospects for Xenografting", <u>Curr. Opinions Immunol.</u> , 1994, <u>6</u> , 765-769
	Fridkis-Hareli, et al., "Copolymer 1 Displaces MBP, PLP and MOG, but Can Not be Displaced by these Antigens from the MHC Class II Binding Site", <u>Department of Chemical Immunology, The Weizmann Institute of Science</u> , 1994
	Fridkis-Hareli, et al., "Direct Binding of Myelin Basic Protein and Synthetic Copolymer 1 to Class II Major Histocompatibility Complex Molecules on Living Antigen-Presenting Cells - Specificity and Promiscuity", <u>Proc. Natl. Acad. Sci. USA</u> , 1994, <u>91</u> , 4872-4876
	Fridkis-Hareli, et al., "Specific and Promiscuous Binding of Synthetic Copolymer 1 to Class II Major Histocompatibility Complex Molecules on Living Antigen Presenting Cells", <u>Israeli Biochem. Soc.</u> , 1994, 21-22 (Abstract)
	Fridkis-Hareli, et al., "Synthetic Copolymer 1 Inhibits the Binding of MBP, PLP and MOG Peptides to Class II Major Histocompatibility Complex Molecules on Antigen Presenting Cells" in <u>Neurochem Mtg.</u> , August 14-19, 1994
	Fridkis-Hareli, et al., "Synthetic Copolymer 1 Inhibits the Binding of MBP, PLP and MOG Peptides to Class II Major Histocompatibility Complex Molecules on Antigen- Presenting Cells", <u>J. Neurochem.</u> , 1994, <u>63</u> (Suppl. I), 561
	Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein do not Require Processing Prior to Binding to Class II Major Histocompatibility Complex Molecules on Living Antigen Presenting Cells", <u>Department of Chemical Immunology, The Weizmann Institute of Science</u> , Rehovot, Israel, 1994

EXAMINER

DATE CONSIDERED

8-27-02

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED  
JUL 09 2002  
TECH CENTER 1600

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeDocket No.  
60772-PCT-USSerial No.  
09/768,872

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

JUL 05 2002  
FIRENCE & TRADEMARKS REC'D  
JC5Applicants  
Rina Aharoni et al.Filing date  
January 23, 2001Group Art Unit  
1644

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein Do Not Require Processing Prior to Binding to Class II Major Histocompatibility Complex Molecules on Living Antigen-Presenting Cells", Cell. Immunol., 1995, 163, 229-236

Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein Do Not Undergo Processing Prior to the Binding to Class II Major Histocompatibility Complex Molecules on Antigen Presenting Cells", Israeli Immunol. Soc., May 3-4, 1994 (Abstract)

Jacobs, et al., "Advances in Specific Therapy for Multiple Sclerosis", Neurol., 1994, 7, 250-254

Johnson, "Experimental Therapy of Relapsing-Remitting Multiple Sclerosis with Copolymer-1", Ann. Neurol., 1994, 36(Suppl.), 115-117

Kott, et al., "COP-1 Increases Suppressor Cells Number in Multiple Sclerosis", Israel Neurological Assoc., December 19-20, 1994, Herzliya (Israel), 17

Mengle-Gaw, "The Major Histocompatibility Complex (MHC)", in Encycl. Molecular Bio. (Oxford Blackwell Science Ltd, 1994) 602-606

Milo, et al., "Additive Effects of COP-1 and IFN-Beta on Immune Responses to Myelin Basic Protein", Neurol., 1994, 44(Suppl. 2), A212

Milo et al., "Additive Effect of Copolymer-1 and Interferon-B on the Immune Response to Myelin Basic Protein", Assaf Harofeh Medical Center, Sackler School of Medicine, Tel-Aviv University of Maryland School of Medicine, 1994, 22

Milo, et al., "Copolymer-1 and Interferon- $\beta$  Additively Suppress the Immune Response to Myelin Basic Protein by Inhibiting Antigen Presentation", J. Neuroimmunol., 1994, 54, 183 (Abstract)

Nightingale, et al., "Access to Investigational Drugs for Treatment Purposes", Am. Family Physician, 1994, 50(4), 845-847

Tisch et al., "Antigen-specific immunotherapy: Is it a Real Possibility to Combat T-Cell-Mediated autoimmunity?" Proc. Natl. Acad. Sci. U.S.A., 1994, 91, 437-438

Schlegel, et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", Blood, 1994, 84(8), 2802-2810

Stark, "Expanded Clinical Trials of Treatments for Multiple Sclerosis (MS): Copolymer 1 (COP-1) Treatment Investigational New Drug (IND) Program", Ann. Neurol., 1994, 36, 114-115

EXAMINER

DATE CONSIDERED

6-7-02

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeDocket No.  
60772-PCT-USSerial No.  
09/768,872

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

JUL 05 2002

Applicants  
Rina Aharoni et al.

Filing date

January 23, 2001

Group Art Unit  
1644

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Teitelbaum, et al., "Immunological Parameters in a Multicenter Clinical Trial of COP1 in Multiple Sclerosis (MS) : A 2-year Follow-up", <u>Neurology</u> , 1994, <u>44</u> (Suppl. 2), A358
	Milo, et al., "Additive Effects of Copolymer-1 and Interferon $\beta$ -1b on the Immune Response to Myelin Basic Protein", <u>J. Neuroimmunol.</u> , 1995, <u>61</u> , 185-193
	O'Connor, et al., "Powders" in <u>The Science and Practice of Pharmacy</u> , Remington, 1995, <u>2</u> , 1598-1614
	Porter, "Coating of Pharmaceutical Dosage Forms," in <u>The Science and Practice of Pharmacy</u> , Remington, 1995, <u>2</u> , 1650-1659
	Reilly, Jr., W.J., "Pharmaceutical Necessities" in <u>The Science and Practice of Pharmacy</u> , Remington 1995, <u>2</u> , 1380-1416
	Schlegel, et al., "Inhibition of Allore cognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in <u>Am. Soc. Hematology, 37<sup>th</sup> Annual Meeting</u> , Seattle, WA (USA), December 1-5, 1995, 224a (Abstract)
	Ben-Nun, et al., "The Autoimmune Reactivity to Myelin Oligodendrocyte Glycoprotein (MOG) in Multiple Sclerosis is Potentially Pathogenic: Effect of Copolymer 1 on MOG-induced Disease", <u>J. Neurol.</u> , 1996, <u>243</u> (Suppl. 1), S14-S22
	Johnson, Management of Relapsing/Remitting Multiple Sclerosis with Copolymer 1 (Copaxone)", <u>Chemical Abstracts</u> , 1996, <u>125</u> , 291993b
	Sykes, "Immunobiology of Transplantation", <u>Faseb J.</u> , 1996, <u>10</u> , 721-730
	Teitelbaum, et al., "Copolymer 1 Inhibits Chronic Relapsing Experimental Allergic Encephalomyelitis Induced by Proteolipid Protein (PLP) Peptides in Mice and Interferes with PLP-specific T Cell Responses", <u>J. Neuroimmunol.</u> , 1996, <u>64</u> , 209-217
	Aharoni, et al., "Studies on the Mechanism and Specificity of the Effect of the Synthetic Random Copolymer GLAT on Graft-versus-Host Disease", <u>Immunol. Letters</u> , 1997, <u>58</u> , 79-87
	Puri et al., "Modulation of the Immune Response in Multiple Sclerosis", <u>J. Immunol.</u> , 1997, <u>158</u> , 2471-2476
	Tarcic et al., "Copolymer 1 (Copaxone) from an Idea to a Drug for Treatment of Multiple Sclerosis" Database HCPLUS on STN, Israel: AN 1997:333270. Kim, Handasa Kim, 1997, <u>281</u> (14), 16-18 (Abstract)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

JUL 09 2002

TECH CENTER 1600/2000

